Security record · archived quarter
BNTX
BioNTech SE · Healthcare · Biotechnology
11Tracked holders
—Δ holders
15.47MShares held
$1.24BReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 94 | 0 | 32.40M | $3.02B | +8 | −8 |
| Q1 2026 | 95 | +4 | 29.16M | $2.59B | +13 | −9 |
| Q4 2025 | 91 | +4 | 29.39M | $2.80B | +4 | — |
| Q3 2025 | 13 | +1 | 23.37M | $2.30B | +1 | — |
| Q2 2025 | 9 | -3 | 22.65M | $2.41B | +1 | −4 |
| Q1 2025 | 10 | -2 | 14.39M | $1.31B | — | −2 |
| Q4 2024 | 12 | -1 | 14.53M | $1.66B | +1 | −2 |
| Q3 2024 | 12 | +1 | 13.93M | $1.65B | +3 | −2 |
| Q2 2024 | 11 | — | 15.47M | $1.24B | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 8.28M | — | $665.08M | 0.5% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 8.28M | — | $665.08M | 0.5% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 8.28M | — | $665.08M | 0.5% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 8.28M | — | $665.08M | 0.5% | n/c | 1 | SEC ↗ |
| 5 | PRIMECAP Management ✦ | 4.79M | — | $384.89M | 0.3% | n/c | 1 | SEC ↗ |
| 6 | Capital World Investors ✦ | 955.98K | — | $76.82M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 654.12K | — | $52.56M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 461.71K | — | $37.10M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 101.50K | — | $8.16M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 68.55K | — | $5.51M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 66.21K | — | $5.32M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 66.21K | — | $5.32M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 52.20K | — | $4.20M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 35.98K | — | $2.89M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 11.65K | — | $936,435 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 272 holders, 47.28M shares, $3.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API